Market Place
Sourcing Support
Novo Nordisk offloads preclinical cancer candidate from $1.1B Forma buyout
02 Mar 2023 //
ENDPTS
Rigel wins US approval of rival drug to Servier leukemia treatment
03 Dec 2022 //
BIOPHARMADIVE
Novo Nordisk announces the completion of the Forma Therapeutics acquisition
14 Oct 2022 //
GLOBENEWSWIRE
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
01 Sep 2022 //
PRESS RELEASE
Forma Therapeutics Reports Second Quarter 2022 Financial Results
05 Aug 2022 //
BUSINESSWIRE
Rigel bets $230M on Forma`s leukemia drug
02 Aug 2022 //
FIERCEBIOTECH
Rigel and Forma Announce Licensing Agreement for Olutasidenib in r/r AML
02 Aug 2022 //
PRNEWSWIRE
Forma Therapeutics to Report Second Quarter 2022 Financial Results
29 Jul 2022 //
BUSINESSWIRE
Forma Therapeutics Announces Appointment of New Executive Team Members
30 Jun 2022 //
BUSINESSWIRE
Forma Therapeutics Announces Presentations at Upcoming Hematology Conference
10 Jun 2022 //
BUSINESSWIRE
Forma Therapeutics to Present at the Jefferies Healthcare Conference
03 Jun 2022 //
BUSINESSWIRE
Forma Therapeutics Highlights Etavopivat Development Expansion and more
26 May 2022 //
BUSINESSWIRE
Forma Therapeutics Reports First Quarter 2022 Financial Results
06 May 2022 //
BUSINESSWIRE
Forma Therapeutics to Report Q1 2022 Financial Results
29 Apr 2022 //
BUSINESSWIRE
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
08 Feb 2022 //
BUSINESSWIRE
Forma`s Olutasidenib+Azacitidine Yields Durable Complete Remission in mIDH1 AML
16 Dec 2021 //
BUSINESSWIRE
Forma`s Investigational Once-Daily Etavopivat Shows Improvement in SCD
11 Dec 2021 //
BUSINESSWIRE
Forma Reports Q3 2021 Financial Results and Provides Business Update
12 Nov 2021 //
BUSINESSWIRE
Forma Therapeutics’ Announces Results of FT-7051 Ongoing Phase 1 Study in mCRPC
07 Oct 2021 //
BUSINESSWIRE
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Updates
13 Aug 2021 //
BUSINESSWIRE
Forma Therapeutics to Report Second Quarter 2021 Financial Results
06 Aug 2021 //
BUSINESSWIRE
Forma Therapeutics to Report Second Quarter 2021 Financial Results
06 Aug 2021 //
BUSINESSWIRE
Forma Announces Appointment of Industry Veteran John E. Bishop as CTO
14 Jun 2021 //
BUSINESSWIRE
Forma Therapeutics Presents New Phase 1 Data on Etavopivat
11 Jun 2021 //
BUSINESSWIRE
Forma Therapeutics Presents New Phase 1 Data on Etavopivat
11 Jun 2021 //
BUSINESSWIRE
Forma to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO
20 May 2021 //
BUSINESSWIRE
Forma sees data `supporting` sickle cell therapy dosing levels LianBio Tarsus
31 Mar 2021 //
ENDPTS
Forma Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data
30 Mar 2021 //
BUSINESSWIRE
Forma sees data `supporting` sickle cell therapy dosing levels; LianBio
30 Mar 2021 //
ENDPTS
Forma builds case for FT-4202 in competitive sickle cell space
30 Mar 2021 //
FIERCEBIOTECH
Forma doses first patient in Phase I prostate cancer treatment trial
20 Jan 2021 //
CLINICALTRIALSARENA
Forma Announces First Patient Dosed in Ph1 Clinical Trial Evaluating FT-7051
20 Jan 2021 //
BUSINESSWIRE
Forma Therapeutics Launches Proposed Public Offering
08 Dec 2020 //
BUSINESSWIRE
Divergent results from Agios, Forma trials for their sickle cell disease drugs
08 Dec 2020 //
STATNEWS
Forma Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH
07 Dec 2020 //
BUSINESSWIRE
Forma Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH
07 Dec 2020 //
BUSINESSWIRE
Forma Announces FT-4202 Receives Orphan Drug Designation in Europe
10 Nov 2020 //
BIOSPACE
Forma Announces Four Oral and Poster Presentations on FT-4202
04 Nov 2020 //
NASDAQ
Forma Announces Four Oral and Poster Presentations on FT-4202
04 Nov 2020 //
BUSINESSWIRE
Forma takes aim at Agios with new AML complete remission data
26 Oct 2020 //
ENDPTS
Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Functions
15 Sep 2020 //
BUSINESSNEWS WIRE
Forma Therapeutics Announces Closing of Initial Public Offering and Exercise
23 Jun 2020 //
BUSINESSWIRE
Forma, Repare snag nearly $500M collectively in upsized IPOs
20 Jun 2020 //
FIERCE BIOTECH
Forma Therapeutics Announces Pricing of Initial Public Offering
18 Jun 2020 //
BUSINESS WIRE
On a hiring spree, Moderna recruits another Amgen vet for executive committee
15 Jun 2020 //
ENDPTS
Forma Presents Safety, Pharmacokinetic & Pharmacodynamic Ph 1 Trial FT-4202
11 Jun 2020 //
BUSINESSWIRE
Forma Therapeutics Announces Ph I Clinical for Investigational Agent FT-4202
09 Jun 2020 //
BUSINESSWIRE
Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs
01 Jun 2020 //
XCONOMY
Forma Therapeutics Announces Clinical Data to be Presented at ASCO20
28 May 2020 //
BUSINESSWIRE
Forma Therapeutics Announces Clinical Data to be Presented at ASCO20
28 May 2020 //
BUSINESSWIRE
Forma Announces Preclinical Data Activity of a Potent Inhibitor of CBP/p300
21 Apr 2020 //
BUSINESSWIRE
FORMA Therapeutics Receives FDA Orphan Drug Designation for FT-4202
15 Apr 2020 //
BUSINESSWIRE
FORMA Therapeutics Receives FDA Orphan Drug Designation for FT-4202
15 Apr 2020 //
BUSINESSWIRE
FORMA`s AnnouncesFT-4202 Granted Fast Track Designation & Rare Pediatric Disease
20 Feb 2020 //
BUSINESSWIRE
FORMA Therapeutics Announces Publication of Olutasidenib’s Molecular Design
13 Feb 2020 //
BUSINESSWIRE
FORMA Therapeutics Announces Closing of $100 Million Series D Financing
19 Dec 2019 //
BUSINESS WIRE
